astrazeneca glp 1 drug Type 2 Diabetes: AstraZeneca's New Oral GLP-1 Led to 10.5% Weight Loss AstraZeneca targets obesity market with
Description
This review summarizes recent advancements and discusses their implications for future therapeutic applications in diabesity management
The 4mg dose had the least side effects as wed expect, and in general has a tolerability profile of tirzepatide with the caveat of a little bit more diarrhea
The approach involves regular monitoring and support to ensure adherence and effectiveness
France NL, Syed YY
